← All trials
NCT04851860
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2021
- Primary completion
- Oct 15, 2021
- Completion date
- Nov 20, 2021
- First posted
- Apr 21, 2021
- Last posted
- Apr 21, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zagazig UniversityLead sponsor
- Zagazig UniversityReponsible party - principal investigator
- Zagazig UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.